WTO Talks Hit a Wall: The Vaccine Waiver Standstill
It’s been a whole year since South Africa and India put forward a bold move to temporarily lift IP rules for Covid‑19 shots and treatments at the WTO. Today, the negotiations are stuck in a ruts, the buzz of hope turned into a polite sigh.
Backstory: The Great Promise
More than a hundred nations signed onto the waiver, twirling visions of a world where vaccine shortages shrink as local plants go live on the ground. The idea? Let developing countries lift the IP lock, gear up production, and give the world more shots.
Deadlock in Minutes
During a hush‑hush TRIPS Council session, Norway’s own Dagfinn Sorli sounded a mix of frustration and yawn. “Where do we go from here?” he asked. He then nudged the room forward: “I definitely need your advice.”
China flagged the talk as a loop‑cycle with nowhere in sight. An Indian delegate scoffed that some voices had done everything to keep the table from moving.
Opposition Persists
- Countries that house big pharma giants—think Switzerland—remain bleary-eyed skeptics.
- They question whether a waiver truly tackles real‑life roadblocks like raw‑material shortages or endless supply‑chain hiccups.
What’s Next: The Ministerial Conference
With a major ministerial meeting set for Nov‑Dec, the WTO has one last crack at sealing trade deals, including any quick fixes for IP. It’s a rare chance to finally lock in a new pact.
Calls for Action From NGOs
Doctors Without Borders wrote that President Biden should temper the strikers and encourage them to change tune. “This would pave the way for more manufacturers, boosting life‑saving shots for everyone,” they said.
WTO Director‑General Ngozi Okonjo‑Iweala has pinched vaccine‑equity solutions as a top priority, amid fresh questions about the trade body’s relevance.
